CCN2 and pulmonary fibrosis: The expression of CTGF in healthy humans is usually very low, but increases significantly during pulmonary fibrosis development, leading to enhanced intensity of TGF-β synthesis, ECM component depositions and suppression of ECM degradation due to inhibition of metalloproteinases [420].